1887

Abstract

Barrett’s oesophagus (BO) is a complicated condition at the gastroesophageal junction in which normal squamous epithelium is changed to columnar and leads to oesophageal adenocarcinoma (OA). In the past decades, the prevalence of Barrett’s disease and mortality rate of adenocarcinoma has significantly increased throughout the word. Data has shown that molecular pathogenesis of disease has not been clearly identified. However, a wide-range and successful administration of probiotics in cancer and gastrointestinal diseases has lead to the investigation into the possible inhibitory role of probiotics in oesophageal cancer. This study was conducted to evaluate the inhibitory effect of probiotics on the expression of biomarkers in an model. Two different Barrett’s oesophageal cell lines were selected to co-culture with and to measure expression of IL-18, TNFα, p53 (tumour suppressor gene), cyclooxygenase 2 and CDX1 (caudal type homeobox 1) genes. In addition, two different aspects of probiotic administration, therapeutic and prophylactic test were also examined. Results showed that micro-organisms could inhibit expression of biomarkers and therapeutic culture conditions were more effective than prophylactic tests. The results obtained suggest that it is possible to incorporate the administration of probiotics in BO and OA prevention.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000039
2015-04-01
2019-12-13
Loading full text...

Full text loading...

/deliver/fulltext/jmm/64/4/348.html?itemId=/content/journal/jmm/10.1099/jmm.0.000039&mimeType=html&fmt=ahah

References

  1. Akatsu H., Iwabuchi N., Xiao J. Z., Matsuyama Z., Kurihara R., Okuda K., Yamamoto T., Maruyama M.. ( 2013;). Clinical effects of probiotic B. longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding. . JPEN J Parenter Enteral Nutr 37:, 631–640. [CrossRef][PubMed]
    [Google Scholar]
  2. Allen S. J., Wareham K., Bradley C., Harris W., Dhar A., Brown H., Foden A., Cheung W. Y., Gravenor M. B. et al. ( 2012;). A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. . BMC Infect Dis 12:, 108–116. [CrossRef][PubMed]
    [Google Scholar]
  3. Babar M., Ryan A. W., Anderson L. A., Segurado R., Turner G., Murray L. J., Murphy S. J., Johnston B. T., Comber H. et al. ( 2012;). Genes of the interleukin-18 pathway are associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma. . Am J Gastroenterol 107:, 1331–1341. [CrossRef][PubMed]
    [Google Scholar]
  4. Baldwin C., Millette M., Oth D., Ruiz M. T., Luquet F. M., Lacroix M.. ( 2010;). Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. . Nutr Cancer 62:, 371–378. [CrossRef][PubMed]
    [Google Scholar]
  5. Bermudez-Brito M., Plaza-Díaz J., Muñoz-Quezada S., Gómez-Llorente C., Gil A.. ( 2012;). Probiotic mechanisms of action. . Ann Nutr Metab 61:, 160–174. [CrossRef][PubMed]
    [Google Scholar]
  6. Blackett K. L., Siddhi S. S., Cleary S., Steed H., Miller M. H., Macfarlane S., Macfarlane G. T., Dillon J. F.. ( 2013;). Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett’s and oesophageal carcinoma: association or causality?. Aliment Pharmacol Ther 37:, 1084–1092. [CrossRef][PubMed]
    [Google Scholar]
  7. Fichter C. D., Herz C., Münch C., Opitz O. G., Werner M., Lassmann S.. ( 2011;). Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells. . BMC Cell Biol 12:, 13. [CrossRef][PubMed]
    [Google Scholar]
  8. Floch M. H., Walker W. A., Madsen K., Sanders M. E., Macfarlane G. T., Flint H. J., Dieleman L. A., Ringel Y., Guandalini S. et al. ( 2011;). Recommendations for probiotic use-2011 update. . J Clin Gastroenterol 45: (Suppl), S168–S171. [CrossRef][PubMed]
    [Google Scholar]
  9. Furrie E., Macfarlane S., Kennedy A., Cummings J. H., Walsh S. V., O’neil D. A., Macfarlane G. T.. ( 2005;). Synbiotic therapy (B. longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. . Gut 54:, 242–249. [CrossRef][PubMed]
    [Google Scholar]
  10. Girardin M., Seidman E. G.. ( 2011;). Indications for the use of probiotics in gastrointestinal diseases. . Dig Dis 29:, 574–587. [CrossRef][PubMed]
    [Google Scholar]
  11. Grover S., Rashmi H. M., Srivastava A. K., Batish V. K.. ( 2012;). Probiotics for human health -new innovations and emerging trends. . Gut Pathog 4:, 15. [CrossRef][PubMed]
    [Google Scholar]
  12. Haarman M., Knol J.. ( 2006;). Quantitative real-time PCR analysis of fecal Lactobacillus species in infants receiving a prebiotic infant formula. . Appl Environ Microbiol 72:, 2359–2365. [CrossRef][PubMed]
    [Google Scholar]
  13. Hashimoto N.. ( 2012;). Expression of COX2 and p53 in rat esophageal cancer induced by reflux of duodenal contents. . ISRN Gastroenterol 2012:, 914824. [CrossRef][PubMed]
    [Google Scholar]
  14. Hvid-Jensen F., Pedersen L., Drewes A. M., Sørensen H. T., Funch-Jensen P.. ( 2011;). Incidence of adenocarcinoma among patients with Barrett’s esophagus. . N Engl J Med 365:, 1375–1383. [CrossRef][PubMed]
    [Google Scholar]
  15. Khailova L., Mount Patrick S. K., Arganbright K. M., Halpern M. D., Kinouchi T., Dvorak B.. ( 2010;). B. bifidum reduces apoptosis in the intestinal epithelium in necrotizing enterocolitis. . Am J Physiol Gastrointest Liver Physiol 299:, G1118–G1127. [CrossRef][PubMed]
    [Google Scholar]
  16. Khan M. W., Zadeh M., Bere P., Gounaris E., Owen J., Klaenhammer T., Mohamadzadeh M.. ( 2012;). Modulating intestinal immune responses by lipoteichoic acid-deficient Lactobacillus acidophilus. . Immunotherapy 4:, 151–161. [CrossRef][PubMed]
    [Google Scholar]
  17. Kim Y., Lee D., Kim D., Cho J., Yang J., Chung M., Kim K., Ha N.. ( 2008;). Inhibition of proliferation in colon cancer cell lines and harmful enzyme activity of colon bacteria by B. adolescentis SPM0212. . Arch Pharm Res 31:, 468–473. [CrossRef][PubMed]
    [Google Scholar]
  18. Kun C., Liang N., Luo X., Zhang T. C.. ( 2013;). Lactobacillus acidophilus strain suppresses the transcription of proinflammatory-related factors in human HT-29 cells. . J Microbiol Biotechnol 23(1):, 64–68. [CrossRef][PubMed]
    [Google Scholar]
  19. Kwon H.-S., Yang E. H., Lee S.-H., Yeon S.-W., Kang B.-H., Kim T.-Y.. ( 2005;). Rapid identification of potentially probiotic B. species by multiplex PCR using species-specific primers based on the region extending from 16S rRNA through 23S rRNA. . FEMS Microbiol Lett 250:, 55–62. [CrossRef][PubMed]
    [Google Scholar]
  20. Lee N. K., Park J. S., Park E., Paik H. D.. ( 2007;). Adherence and anticarcinogenic effects of Bacillus polyfermenticus SCD in the large intestine. . Lett Appl Microbiol 44:, 274–278. [CrossRef][PubMed]
    [Google Scholar]
  21. Lim Y. C., Fitzgerald R. C.. ( 2013;). Diagnosis and treatment of Barrett’s oesophagus. . Br Med Bull 107:, 117–132. [CrossRef][PubMed]
    [Google Scholar]
  22. Macfarlane G. T., Cummings J. H.. ( 2002;). Probiotics, infection and immunity. . Curr Opin Infect Dis 15:, 501–506. [CrossRef][PubMed]
    [Google Scholar]
  23. Macfarlane G. T., Steed H., Macfarlane S.. ( 2008;). Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. . J Appl Microbiol 104:, 305–344.[PubMed]
    [Google Scholar]
  24. Madsen K. L.. ( 2012;). Enhancement of epithelial barrier function by probiotics. . J Epithel Biol Pharmacol 5:, 55–59. [CrossRef]
    [Google Scholar]
  25. Makita K., Kitazawa R., Semba S., Fujiishi K., Nakagawa M., Haraguchi R., Kitazawa S.. ( 2013;). Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett’s esophagus. . World J Gastroenterol 19:, 536–541. [CrossRef][PubMed]
    [Google Scholar]
  26. Malaguarnera G., Leggio F., Vacante M., Motta M., Giordano M., Bondi A., Basile F., Mastrojeni S., Mistretta A. et al. ( 2012;). Probiotics in the gastrointestinal diseases of the elderly. . J Nutr Health Aging 16:, 402–410. [CrossRef][PubMed]
    [Google Scholar]
  27. Mozaffari namin B., Soltan Dallal M. M., Daryani N. E.. ( 2015;). The effect of Campylobacter concisus on the expression of IL18, TNFα, and p53 on Barrett's oesophagus. . J J Microbiol (in press).
    [Google Scholar]
  28. Ng S. C., Hart A. L., Kamm M. A., Stagg A. J., Knight S. C.. ( 2009;). Mechanisms of action of probiotics: recent advances. . Inflamm Bowel Dis 15:, 300–310. [CrossRef][PubMed]
    [Google Scholar]
  29. Nguyen G. H., Schetter A. J., Chou D. B., Bowman E. D., Zhao R., Hawkes J. E., Mathé E. A., Kumamoto K., Zhao Y. et al. ( 2010;). Inflammatory and microRNA gene expression as prognostic classifier of Barrett’s-associated esophageal adenocarcinoma. . Clin Cancer Res 16:, 5824–5834. [CrossRef][PubMed]
    [Google Scholar]
  30. Otte J.-M., Mahjurian-Namari R., Brand S., Werner I., Schmidt W. E., Schmitz F.. ( 2009;). Probiotics regulate the expression of COX-2 in intestinal epithelial cells. . Nutr Cancer 61:, 103–113. [CrossRef][PubMed]
    [Google Scholar]
  31. Quigley E. M. M.. ( 2012;). Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. . Nutr Clin Pract 27:, 195–200. [CrossRef][PubMed]
    [Google Scholar]
  32. Rijkers G. T., de Vos W. M., Brummer R. J., Morelli L., Corthier G., Marteau P.. ( 2011;). Health benefits and health claims of probiotics: bridging science and marketing. . Br J Nutr 106:, 1291–1296. [CrossRef][PubMed]
    [Google Scholar]
  33. Russo A., Bronte G., Cabibi D., Bazan V., Cicero G., Bertani A., Rizzo S., Fiorentino E.. ( 2013;). The molecular changes driving the carcinogenesis in Barrett’s esophagus: Which came first, the chicken or the egg?. Crit Rev Oncol Hematol 86:, 278–289. [CrossRef][PubMed]
    [Google Scholar]
  34. Sharma P., Hawes R. H., Bansal A., Gupta N., Curvers W., Rastogi A., Singh M., Hall M., Mathur S. C. et al. ( 2013;). Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial. . Gut 62:, 15–21. [CrossRef][PubMed]
    [Google Scholar]
  35. Smith A. R., Macfarlane G. T., Reynolds N., O’May G. A., Bahrami B., Macfarlane S.. ( 2012;). Effect of a synbiotic on microbial community structure in a continuous culture model of the gastric microbiota in enteral nutrition patients. . FEMS Microbiol Ecol 80:, 135–145. [CrossRef][PubMed]
    [Google Scholar]
  36. Soltan Dallal M. M., Yazdi M. H., Holakuyee M., Hassan Z. M., Abolhassani M., Mahdavi M.. ( 2012;). Lactobacillus casei ssp.casei induced Th1 cytokine profile and natural killer cells activity in invasive ductal carcinoma bearing mice. . Iran J Allergy Asthma Immunol 11:, 183–189.[PubMed]
    [Google Scholar]
  37. Steed H., Macfarlane G. T., Blackett K. L., Bahrami B., Reynolds N., Walsh S. V., Cummings J. H., Macfarlane S.. ( 2010;). Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn’s disease. . Aliment Pharmacol Ther 32:, 872–883. [CrossRef][PubMed]
    [Google Scholar]
  38. Thrift A. P., Garcia J. M., El-Serag H. B.. ( 2014;). A multibiomarker risk score helps predict risk for Barrett’s esophagus. . Clin Gastroenterol Hepatol 12:, 1267–1271. [CrossRef][PubMed]
    [Google Scholar]
  39. Weng M., Walker W. A.. ( 2013;). The role of gut microbiota in programming the immune phenotype. . J Dev Orig Health Dis 4:, 203–214. [CrossRef][PubMed]
    [Google Scholar]
  40. Werner M., Laßmann S.. ( 2012;). [Update on Barrett esophagus and Barrett carcinoma]. . Pathologe 33: (Suppl. 2), 253–257 (in German). [CrossRef][PubMed]
    [Google Scholar]
  41. Yazdi M. H., Soltan Dallal M. M., Hassan Z. M., Holakuyee M., Agha Amiri S., Abolhassani M., Mahdavi M.. ( 2010;). Oral administration of Lactobacillus acidophilus induces IL-12 production in spleen cell culture of BALB/c mice bearing transplanted breast tumour. . Br J Nutr 104:, 227–232. [CrossRef][PubMed]
    [Google Scholar]
  42. Zanello G., Berri M., Dupont J., Sizaret P.-Y., D’Inca R., Salmon H., Meurens F.. ( 2011;). Saccharomyces cerevisiae modulates immune gene expressions and inhibits ETEC-mediated ERK1/2 and p38 signaling pathways in intestinal epithelial cells. . PLoS ONE 6:, e18573. [CrossRef][PubMed]
    [Google Scholar]
  43. Zhu Y., Michelle Luo T., Jobin C., Young H. A.. ( 2011;). Gut microbiota and probiotics in colon tumorigenesis. . Cancer Lett 309:, 119–127. [CrossRef][PubMed]
    [Google Scholar]
  44. Zimmerman T. G.. ( 2014;). Common questions about Barrett esophagus. . Am Fam Physician 89:, 92–98.[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000039
Loading
/content/journal/jmm/10.1099/jmm.0.000039
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error